<DOC>
	<DOCNO>NCT00182819</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether radiation therapy effective temozolomide treat glioma . PURPOSE : This randomized phase III trial study radiation therapy see well work compare temozolomide treat patient glioma .</brief_summary>
	<brief_title>Radiation Therapy Temozolomide Treating Patients With Gliomas</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare progression-free survival patient low-grade glioma treat radiotherapy v temozolomide . Secondary - Compare overall survival patient treat regimen . - Determine whether incidence late toxicity decrease patient randomized receive temozolomide . - Compare toxic effect regimens patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , control , multicenter study . Patients stratify accord participate center , chromosome 1p status ( delete v normal v undeterminable ) , contrast enhancement MRI ( yes v ) , age ( &lt; 40 year vs ≥ 40 year ) , WHO performance status ( 0 1 v 2 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo radiotherapy daily , 5 day week , total 28 fraction ( i.e. , 5½ week ) . - Arm II : Patients receive oral temozolomide daily day 1-21 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . Quality life assess baseline every 3 month disease progression . After completion study treatment , patient follow every 6 month survival . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A minimum 699 patient ( total 466 randomize [ 233 per treatment arm ] ) accrue study within 5 year .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm lowgrade glioma , include follow type : Astrocytoma ( gemistocytic , fibrillary , protoplasmatic ) Oligoastrocytoma Oligodendroglioma WHO grade II disease Supratentorial tumor location RTOG neurological function 03 Not candidate surgical treatment alone Requires treatment , determine ≥ 1 follow criterion : Age ≥ 40 year Radiologicallyproven progressive lesion New worsen neurological symptom seizure ( e.g. , focal deficit , sign increase intracranial pressure , mental deficit ) Intractable seizure , define follow criterion : Experiences persistent seizure interfere everyday life activity except drive car Failed 3 antiepileptic drug regimen , include ≥ 1 combination regimen Tumor material ( paraffinembedded ) histopathologic slide available PATIENT CHARACTERISTICS : Age 18 Performance status WHO 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic No chronic hepatitis B C infection Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Renal Creatinine ≤ 1.5 time ULN Other Not pregnant nursing Fertile patient must use effective contraception 6 month completion study treatment No known HIV positivity No serious medical condition No prior concurrent malignancy except surgically cure carcinoma situ cervix nonmelanoma skin cancer No psychological , familial , sociological , geographical condition would preclude study participation No medical condition would preclude receive oral medication ( e.g. , frequent vomit partial bowel obstruction ) PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent growth factor elevate absolute neutrophil count purpose temozolomide administration No concurrent epoetin alfa No concurrent immunotherapy biologic therapy Chemotherapy No prior chemotherapy No concurrent chemotherapy , include adjuvant chemotherapy patient randomize undergo radiotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy brain No concurrent integrate boost intensitymodulated radiotherapy Surgery Recovered prior surgery No concurrent surgical tumor debulking Other No prior randomization study No concurrent investigational drug No concurrent regular use agent know radiosensitizers radioprotectors ( e.g. , cyclooxygenase2 inhibitor , thalidomide , amifostine ) study radiotherapy Occasional use nonsteroidal antiinflammatory drug pain allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
	<keyword>adult mixed glioma</keyword>
</DOC>